Properties of the ideal corticosteroid therapy

Allergy and Asthma Proceedings

Volumn 26, Issue 3, 2005, Pages 173-182

  Zitt, Myron J ^a,b,c,d  

^a STONY BROOK UNIVERSITY   (United States)

^b Queens Long Island Medical Group PC   (United States)

^c NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; GLUCOCORTICOID;

ASTHMA; CHEMISTRY; CONFERENCE PAPER; DRUG EFFECT; ESTERIFICATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ASTHMA; ESTERIFICATION; GLUCOCORTICOIDS; HUMANS; TREATMENT OUTCOME;

EID: 24944527032     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (73)

1. Moorman JE, and Mannino DM. Increasing U.S. asthma mortality rates: Who is really dying? J Asthma 38:65-71, 2001.
2. National Asthma Education and Prevention Program. Expert panel report: Guidelines for the diagnosis and management of asthma. Update on selected topics - 2002. J Allergy Clin Immunol 110:S149-S219, 2002.
3. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma. Expert Panel Report 2. National Institutes of Health publication no. 97-4051, July 1997.
4. Barnes PJ, Pedersen S, and Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med. 157(suppl):S1-S53, 1998.
5. Leung DYM, and Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111:3-22, 2003.
6. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109:410-418, 2002.
7. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med 130:487-495, 1999.
8. Sont JK, Willems LNA, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 159:1043-1051, 1999.
9. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. Arch Intern Med 159:941-955, 1999.
10. Affrime MB, Kosoglou T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 118:1538-1546, 2000.
11. Pedersen S, and O'Byrne PM. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 52(suppl 39):1-34, 1997.
12. Leone FT, Fish JE, Szefler SJ, et al. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma. Chest 124:2329-2340, 2003.
13. Agertoft L, and Pedersen S. Lower-leg growth rate and HPA-axis function in children with asthma during treatment with inhaled ciclesonide. J Allergy Clin Immunol 113(suppl 2):S119, 2004.
14. Halpern MT, Scmier JK, Van Kerkhove MD, et al. Impact of long-term inhaled corticosteroid therapy on bone mineral density: Results of a meta-analysis. Ann Allergy Asthma Immunol 92:201-207, 2004.
15. Hanania NA, Chapman KR, and Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 98:196-208, 1995.
16. Israel E, Banerjee TR, Fitzmatirice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 345:941-947, 2001.
17. Wisniewski AF, Lewis SA, Green DJ, et al. Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma. Thorax 52:853-860, 1997.
18. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 355:1399-1403, 2000.
19. Dickerson JE Jr, Dotzel E, and Clark AF. Steroid-induced cataract: New perspective from in vitro and lens culture studies. Exp Eye Res 65:507-516, 1997.
20. Autio P, Karjalainen J, Risteli L, et al. Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. Am J Respir Crit Care Med 153:1172-1175, 1996.
21. Farrell RJ, and Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 178:339-346, 2003.
22. Barnes PJ, and Adcock I. Anti-inflammatory actions of steroids: Molecular mechanisms. Trends Pharmacol Sci 14:436-441, 1993.
23. Tashkin DP. New devices for asthma. J Allergy Clin Immunol 101:S409-S416, 1998.
24. Physicians' Desk Reference, 53rd ed. Montvale, NJ: Medical Economics Co., 1999.
25. Falcoz C, Horton J, Mackie AE, et al. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma. Clin Pharmacokinet 39(suppl 1):31-37, 2000.
26. Bethke TD, Boudreau RJ, Hasselquist BE, et al. High lung deposition of ciclesonide in 2D and 3D imaging. Eur Respir J 20(suppl 38):S109, 2002.
27. Vanden Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 106:1209-1226, 2000.
28. Lipworth BJ, and Jackson CM. Safety of inhaled and intranasal corticosteroids. Drug Safety 23:11-33, 2000.
29. Rohatagi S, Luo Y, Shen L. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid ciclesonide. Am J Ther. In press, 2005.
30. McFadden ER Jr, Dolovich M, and Colice G. The suspension is over: New solutions for the treatment of asthma. Available at: http://www.medscape.com/ viewprogram/2420, accessed May 15, 2004.
31. Leach CL, Davidson PJ, and Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 12:1346-1353, 1998.
32. Howarth PH. Why particle size should affect clinical response to inhaled therapy. J Aerosol Med 14(suppl 1):S27-S34, 2001.
33. Lötvall J, and O'Byrne P. Targeting drugs to the airways by different inhalation devices. Role of deposition characteristics. Biodrugs 12:279-289, 1999.
34. Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med 14(suppl 1):S19-S26, 2001.
35. Borgström L. The pharmacokinetics of inhaled hydrofluoroalkane formulations. J Allergy Clin Immunol 104:S246-S249, 1999.
36. Toogood JH, Jennings B, Greenway RW, et al. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol 65:145-153, 1980.
37. Hochhaus G, Mollmann H, Derendorf H, et al. Pharmacokinetic/ pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 37:881-892, 1997.
38. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 91(suppl A):22-28, 1997.
39. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 101:S440-S446, 1998.
40. Bundschuh DS, Riedel R, Hatzelmann A, et al. Efficacy and safety profile of the novel on-site activated corticosteroid ciclesonide. Am J Respir Crit Care Med 163:A588, 2001.
41. Stoeck M, Riedel R, Hochhaus G, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther 309:249-258, 2004.
42. Boobis AR. Comparative physiochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. Respir Med 92(suppl B):2-6, 1998.
43. Rang HP, and Dale MM (Eds.). Adsorption, distribution, and fate of drugs. In Pharmacology, 2nd ed. New York: Churchill Livingstone, 1991, 79-81.
44. Brattsand R. Drug development of inhaled steroids. A pharmacologist's view based on experiences from the budesonide project. In Inhaled Steroids in Asthma. Optimizing Effects in the Airways. Schleimer RP, O'Byrne PM, Szefler SJ, and Brattsand R (Eds). New York: Marcel Dekker, Inc., 3-33, 2002.
45. Brattsand R. The ideal steroid. Pulm Pharmacol Ther 12:119-122, 1999.
46. Edsbäcker S. Uptake, retention, and biotransformation of corticosteroids in the lung and airways. In Inhaled Steroids in Asthma. Optimizing Effects in the Airways. Schleimer RP, O'Byrne PM, Szefler SJ, and Brattsand R (Eds). New York: Marcel Dekker, Inc., 213-244, 2002.
47. Miller-Larsson A, Axelsson BO, Brattsand R, et al. Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide. Eur Respir J 22(suppl 45):P332, 2003.
48. Edsbäcker S, and Brattsand R. Budesonide fatty-acid esterification: A novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol 88:609-616, 2002.
49. Miller-Larsson A, Jansson P, Runström A, and Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 162:1455-1461, 2000.
50. Miller-Larsson A, Mattsson H, Hjertberg E, et al. Reversible fatty acid conjugation of budesonide: Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 26:623-630, 1998.
51. Tunek A, Sjödin K, and Hallström G. Reversible formation of fatty acid esters of budesonide, an anti-asthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 25:1311-1317, 1997.
52. Nave R, Sättele N, Meyer W, et al. Formation of fatty acid conjugates of ciclesonide-active principle in the rat lung after 4-week inhalation of ciclesonide. Am J Respir Crit Care Med 167:A771, 2003.
53. Hansel T, Engelstaetter R, Benezet O, et al. Once daily ciclesonide (80 μg or 320 μg) is equally effective as budesonide 200 μg given twice daily: A 12-week study in asthma patients. Eur Respir J 22(suppl 45):P2639, 2003.
54. Buhl R, Vinkler I, Magyar P, et al. Once daily ciclesonide is as effective as fluticasone propionate given twice daily in treating patients with asthma. Am J Respir Crit Care Med 169:A91, 2004.
55. Nave R, Hummel RP, Wohlsen A, et al. The active metabolite of ciclesonide, des-isobutyryl ciclesonide, forms highly lipophilic fatty acid conjugates in precision-cut rat lung slices. Am J Respir Crit Care Med 169:A91, 2004.
56. Rohatagi S, Rhodes GR, and Chaikin P. Absolute oral versus inhaled bioavailability: Significance for inhaled drugs with special reference to inhaled glucocorticoids. J Clin Pharmacol 39:661-663, 1999.
57. Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics, and metabolism following intravenous, oral, intranasal, and inhaled administration in man. J Clin Pharmacol 51:400-409, 2001.
58. 14C-ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 43:479-486, 2004.
59. Nave R, Bethke T, Seiberling M, et al. Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects. Eur Respir J. 20(suppl 38):S110, 2002.
60. Kelly HW. Comparative potency and clinical efficacy of inhaled corticosteroids. Respir Care Clin N Am 5:537-553, 1999.
61. Physicians' Desk Reference. Sifton DW (Ed.)., Montvale, NJ: Thompson PDR, 2003, 636-640.
62. Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 43:365-378, 2003.
63. Rowland M, and Tozer TN. Elimination. In Clinical Pharmacokinetics: Concepts and Applications, 3rd ed. Balado D, Klass F, and Stead L (Eds.). Philadelphia, PA: Lippincott Williams & Wilkins, 1995, 156-183.
64. Hochhaus G, Derendorf H, Talton J, et al. Factors involved in the pulmonary targeting of inhaled glucocorticoids. The use of pharmacokinetic/ dynamic simulations. In Inhaled Steroids in Asthma. Optimizing Effects in the Airways. Schleimer RP, O'Byrne PM, Szefler SJ, and Brattsand R (Eds). New York: Marcel Dekker, Inc., 283-305, 2002.
65. Reynolds NA, and Scott LJ. Ciclesonide. Drugs 64:511-519, 2004.
66. Nave R, Zech K, and Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol In press, 2005.
67. Berger WE, Mansfield L, Pinter C, et al. Ciclesonide is well tolerated and has minimal oropharyngeal side effects at once daily doses of 80 μg, 160 μg, and 320 μg in the treatment of patients with mild-to-moderate asthma. J Allergy Clin Immunol 113:S38, 2004.
68. Bernstein JA, Noonan MJ, Rim C, et al. Ciclesonide has minimal oropharyngeal side effects in the treatment of patients with moderate-to-severe asthma. J Allergy Clin Immunol 113:S113, 2004.
69. Lipworth BJ, Kaliner MA, LaForce CF, et al. Comparison of HPA axis suppression with CIC and FP in patients with mild-to-moderate asthma. Ann Allergy Asthma Immunol 94:465-472, 2005.
70. Busse W, Kaliner M, Bernstein D, et al. The novel inhaled corticosteroid ciclesonide is efficacious and has a favorable safety profile in adults and adolescents with severe persistent asthma. J Allergy Clin Immunol 115:a846, 2005.
71. Pearlman D, Creticos P, Lampl K, et al. Once-daily ciclesonide is effective and well-tolerated in adult and adolescent patients with mild-to-moderate asthma. J Allergy Clin Immunol 115:a845, 2005.
72. Shapiro G, Bensch G, Lanier R, et al. Once-daily treatment with ciclesonide is effective and well-tolerated in children with persistet asthma. J Allergy Clin Immunol 115:a20, 2005.
73. Agertoft L, and Pederson S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol In press, 2005.